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Background: Information on the long-term efficacy of intravenous pamidronate ther-
apy in Asian patients with osteogenesis imperfecta (OI) is limited. We report our 
experience using pamidronate in Taiwanese patients with OI.
Methods: Twenty-six patients with type I, III, or IV OI (eight males and 18 females; 
age range at last follow-up, 2.9−39.2 years) who received (or were currently receiving) 
intravenous pamidronate treatment (30 mg/m2/dose, every month) were retrospec-
tively analyzed. Patients were followed for 1.0−7.3 years over the study period from 
February 2000 to October 2007.
Results: The mean standard deviation score (SDS) for bone mineral density (BMD) 
had increased significantly from −4.72 to −3.37 (p < 0.005) after 1 year of treatment. 
In 16 patients evaluated after 4 years and eight after 6 years, the mean SDS continued 
to improve, to −2.69 (p < 0.001) and −1.54 (p < 0.005), respectively. The fracture 
rate decreased significantly (from 2.8 ± 1.1 to 0.6 ± 0.6, p < 0.001), and nine patients 
(35%) had no fractures while receiving treatment. The response to pamidronate was 
significantly better in patients with poorer initial BMD SDS (1 year: r = −0.71, p < 0.01; 
4 years: r = −0.81, p < 0.01).
Conclusion: This retrospective study suggests that Taiwanese patients with OI can 
benefit from pamidronate treatment, leading to a reduced incidence of fractures and 
increased BMD, especially in patients with poor baseline BMD.
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1. Introduction
Osteogenesis imperfecta (OI) (MIM# 166200, 166210, 
259420, and 166220) is a genetic disorder charac-
terized by increased bone fragility and low bone 
mass. It occurs in about 1 in 20,000 births.1 Most 
patients have mutations in the COL1A1 or COL1A2 
genes localized on chromosomes 17 and 7, respec-
tively.2 Sillence et al3 classified OI into four major 
phenotypes, according to clinical severity. Type I is 
the mildest form, with normal or only slightly af-
fected growth and minimal bone deformities. Type II 
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is the most severe form, and is lethal in the peri-
natal period. Type III is severely deforming, with 
fractures often present at birth. These patients 
have extremely short stature with progressive limb 
and spine deformities secondary to multiple frac-
tures. Type IV is moderately deforming, between 
types I and III in terms of its severity. Untreated 
patients have generalized osteopenia, recurrent bone 
fractures and deformities, and growth retardation. 
A variety of treatments, including calcitonin, anabolic 
steroids, vitamins (A, C, and D), and minerals (cal-
cium, fluoride, and magnesium) have been used, but 
have been ineffective in reducing the complications 
of OI.4 Pamidronate is a bisphosphonate and a syn-
thetic analog of pyrophosphate that potently inhib-
its osteoclast activity. It has been shown to increase 
bone mineral density (BMD), decrease fracture rate, 
and substantially improve functional status.5−21 How-
ever, information regarding the long-term efficacy 
of intravenous pamidronate in Asian patients with 
OI is limited.20,21 The aim of this study was to evalu-
ate the effect of monthly infusions of pamidronate on 
BMD, fracture rate, body height and weight change 
in Taiwanese patients with OI. We also assessed the 
factors influencing response to therapy.
2. Patients and Methods
2.1. Subjects
Twenty-six patients with OI (eight males and 18 
females; age range at last follow-up, 2.9−39.2 years) 
who received (or were currently receiving) intra-
venous pamidronate from February 2000 through 
October 2007 at Mackay Memorial Hospital were 
evaluated. Diagnosis and classification, using the 
classification system of Sillence et al,3 were based 
on clinical and radiological characteristics. The in-
clusion criteria were type III (seven patients) or IV 
(13 patients) OI with fractures and pain, or type I 
(six patients) OI with vertebral compression fractures 
or severe osteoporosis.
2.2. Treatment
Pamidronate was diluted in isotonic saline to a con-
centration of less than 0.1 mg/mL and administered 
by intravenous infusion over 4 hours at a dose of 
30 mg/m2, once every month. All subjects also took 
oral calcium carbonate (50 mg/kg/day) during treat-
ment. Patients’ ages at the start of treatment ranged 
from 0.1−37.0 years, and the duration of treatment 
ranged from 1.0−7.3 years (mean, 4.3 ± 2.2 years). 
Written informed consent was obtained from pa-
tients or from parents of patients aged less than 
12 years of age.
2.3. Assessment
We recorded body height, body weight, and any 
fractures or adverse events, each time a patient 
visited for a pamidronate infusion. Height and weight 
were transformed to a standard deviation score (SDS) 
based on a standard growth table for Taiwanese 
children.22 The annual fracture rate was calculated 
based on the reports of parents or on medical re-
cords. The annual fracture incidence was calculated 
beginning 2 years prior to treatment and through-
out the entire treatment period for all except two 
patients (patients 1 and 2), who started treatment 
in their first year of life. BMD was assessed using 
dual-energy x-ray absorptiometry measurements 
of the lumbar spine (L1−L4) using the Hologic QDR 
4500 system (Hologic, Bedford, MA, USA). There are 
currently no adequate reference data for BMD in 
Taiwanese children assessed by this method, and 
normative reference data were therefore obtained 
from the literature.23,24 The BMD results were con-
verted to age- and gender-specific z scores. Accord-
ing to the classification used by our radiologists, 
osteopenia was defined as a z score of lower than 
one standard deviation below the mean (< −1 SD) 
and osteoporosis as a z score of < −2 SD.
2.4. Statistical analysis
Changes in BMD, fracture incidence, and height and 
weight before and after treatment were analyzed 
using Student’s paired t test. Linear regression anal-
ysis and two-way analysis of variance (ANOVA) were 
used to assess the factors associated with an in-
crease in BMD z score at 1 and 4 years after treat-
ment. SPSS version 11.5 (SPSS Inc, Chicago, IL, USA) 
was used, and differences were considered to be 
statistically significant when the p value was < 0.05.
3. Results
The clinical profiles of the 26 participants are listed 
in Table 1. The mean BMD SDS after 1 year had in-
creased significantly from −4.72 to −3.37 (p < 0.005) 
in all 26 subjects. After 4 years, the SDS had im-
proved to −2.69 (p < 0.001) in the 16 patients available 
for evaluation, and after 6 years to −1.54 (p < 0.005) 
in eight evaluable patients. The average 1-, 4-, and 
6-year increments in BMD were 27.2 ± 28.67%, 52.4 ± 
45.38%, and 59.6 ± 44.20%, respectively. Osteoporosis 
was present in 96% (25/26) of patients before treat-
ment, decreasing to 88% (23/26) after 1 year, 75% 
(12/16) after 4 years, and 38% (3/8) after 6 years 
of treatment (Figure). The annual incidence of frac-
tures decreased significantly during treatment (from 
2.8 ± 1.1 to 0.6 ± 0.6, p < 0.001), and nine patients 
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(35%) had no fractures at all while receiving pamid-
ronate. Nine patients (35%) had a family history of 
OI. A poorer initial BMD SDS correlated significantly 
with a greater increase in BMD SDS (1 year: r = −0.71, 
p < 0.01; 4 years: r = −0.81, p < 0.01), indicating a 
better response in patients with poorer bone min-
eralization at the start of treatment. Age at the start 
of treatment was not significantly correlated with 
response (1 year: r = −0.13, p > 0.05; 4 years: r = −0.45, 
p > 0.05) (Table 2). The 1-year increase in BMD SDS 
did not vary significantly with gender, OI type, or 
pre-pubertal versus pubertal status (Table 3). The 
18 pre-pubertal patients grew during treatment, but 
their height and weight SDS after 1 to 4 years of treat-
ment did not change. Twelve patients (46%) experi-
enced low-grade fever during the first pamidronate 
infusion. These 12 patients received acetaminophen 
pretreatment prior to subsequent pamidronate doses, 
and the fever did not recur. No other adverse effects 
were observed.
4. Discussion
This retrospective analysis of 26 patients with OI 
studied over a 7-year period at a medical center in 
Taiwan demonstrated an improvement in BMD and 
a decreased incidence of fractures with monthly 
intravenous pamidronate treatment. Earlier studies 
have also demonstrated clinical benefits of pamid-
ronate in OI, including increased BMD, decreased 
fracture incidence, and substantially improved func-
tional status.5−21 Although ours was a small retro-
spective study with heterogenous disease types and 
lacking a control group, it is the first to demonstrate 
comparable benefits of pamidronate in Taiwanese 
patients with OI.
In 1998, Glorieux et al11 reported on the safety 
and efficacy of intravenous pamidronate in 30 pa-
tients with OI. The mean dose in that series was 
6.8 mg/kg/year, given in divided doses on each of 
3 consecutive days at 4−6-month intervals. This be-
came the basis of the standard protocol for cyclic 
infusions of pamidronate on 3 successive days every 
4 months.9,10,14,17,19 However, this regimen was in-
convenient for patients, and therefore adversely 
affecting compliance. Other investigators reported 
a similar degree of efficacy with a single monthly 
infusion.5−7,13,20 We followed this simplified proto-
col, with beneficial results.
Bajpai et al8 reported that improvement in the 
BMD SDS was not correlated with age at initiation 
of treatment or the initial BMD SDS. We also failed 
to find any correlation with age, but in our study, 
patients with greater deficits in BMD at baseline had 
a more marked improvement in BMD during ther-
apy, consistent with the findings of Rauch et al.16
Zeitlin et al18 reported that 4 years of cyclical 
intravenous pamidronate led to significant height 
gain in patients affected by moderate to severe OI. 
They expressed height as a percentage of the re-
sult expected for untreated patients with the same 
OI type, and found that long-term pamidronate ther-
apy was associated with significant height gain in OI 
types I, III, and IV. No untreated controls were avail-
able for comparison in our study, and we were there-
fore unable to demonstrate such a result. However, 
2
0
n = 26
Baseline
Duration of therapy (yr)
1 4 6
BM
D
 z
 s
co
re −2
−4
−6
−8
−10
n = 26
n = 16 n = 8
Figure Bone mineral density z score (L1−L4) using dual-
energy x-ray absorptiometry in patients with osteogenesis 
imperfecta treated with intravenous pamidronate. Line 
indicates osteoporosis, i.e. a z score of < −2.
Table 2  Factors influencing increase in BMD z score 
after pamidronate treatment for 1 year and 
4 years
Parameter 
1 yr (n = 26) 4 yr (n = 16)
 r p r p
Age at treatment −0.13 NS −0.45 NS
Initial BMD z score −0.71 < 0.01 −0.81 < 0.01
NS = not significant.
Table 3  Factors influencing increase in BMD z score 
after pamidronate treatment for 1 year
Parameter N 
1-year increase in
 p
  BMD z score
Gender
 Male 8 1.17 ± 0.83 NS
 Female 18 1.44 ± 1.65
Type
 I 6 1.59 ± 0.62 NS
 III 7 1.02 ± 1.27
 IV 13 1.43 ± 1.96
Pre-puberty or puberty
 Pre-puberty 18 1.58 ± 1.62 NS
 Puberty 8 0.86 ± 0.68
NS = not significant.
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the mean SDS for height in the pre-pubertal patients 
in our series did not change significantly during the 
course of therapy, compared to a standard growth 
table for Taiwanese children, indicating that their 
height increased steadily, and pamidronate was not 
associated with any growth retardation.
As in previous studies,5,11,19,20 the only signifi-
cant adverse effect we observed during therapy was 
low-grade fever during the first treatment. Patients 
who experienced this flu-like reaction when first ex-
posed to intravenous pamidronate were treated with 
standard doses of acetaminophen prior to subsequent 
doses, and the fever did not recur.
Previous studies reported that pamidronate-
induced osteopetrosis and nephrotoxicity (tubulo-
interstitial nephritis) occurred in a few patients with 
various disorders.25−27 Excessive doses and prolonged 
use of pamidronate could have a cumulative toxic 
effect, and could compromise skeletal quality in 
growing patients, despite concomitant increases in 
bone density. However, the chronic effects of pamidro-
nate on bone metabolism in patients with OI are not 
yet clearly understood. Further studies are needed to 
determine if pamidronate can substantially improve 
the long-term quality of life in patients with OI.
In conclusion, this 7-year retrospective study 
indicated that monthly pamidronate infusions in 
Taiwanese patients with OI were safe and effective. 
The fracture rate decreased and the BMD increased, 
especially in patients with poor initial BMD.
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